Clinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

Kenji Okada, Toshimi Kimura, Hiroshige Mikamo, Kei Kasahara, Masafumi Seki, Shunji Takakura, Issei Tokimatsu, Norio Ohmagari, Yoshiko Takahashi, Kazuaki Matsumoto, Masahiro Igarashi, Masahiro Kobayashi, Yukihiro Hamada, Takahiro Mochizuki, Masao Kimura, Yoshifumi Nishi, Yusuke Tanigawara, Yoshio Takesue

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Arbekacin (ABK) was approved and widely used in Japan for treatment of patients infected with MRSA, and TDM was introduced in clinical practice. The Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring decided to develop a clinical practice guidelines for TDM of ABK for the following reasons. First, although the daily dose of 150e200 mg was approved in Japan, recent PKPD studies revealed that higher serum concentration is required to achieve better clinical efficacy and several findings concerning the usefulness of higher dosage regimen have obtained recently. Second, although maximal concentrations that obtained immediately after the end of administration (Cmax) was generally adopted, the serum concentration at 1 h after initiation of administration [peak serum concentration (Cpeak)] proved to be more suitable as an efficacy indicator of aminoglycosides. Lastly, as ABK is approved only in Japan, no international practice guideline for TDM has not been available in ABK to date. This guideline evaluated the scientific data associated with serum ABK monitoring and provided recommendations based on the available evidence. Potential limitations of this guideline, however, include the findings that few prospective clinical trials of TDM of ABK are available in the treatment of MRSAinfections and that most of the published literature describes observational studies.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalJournal of Infection and Chemotherapy
Volume20
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Drug Monitoring
Practice Guidelines
Drug Therapy
Japan
Serum
Guidelines
Aminoglycosides
Methicillin-Resistant Staphylococcus aureus
Observational Studies
habekacin
Clinical Trials
Therapeutics

Keywords

  • Arbekacin
  • Guideline
  • MRSA
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases
  • Medicine(all)

Cite this

Clinical practice guidelines for therapeutic drug monitoring of arbekacin : A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. / Okada, Kenji; Kimura, Toshimi; Mikamo, Hiroshige; Kasahara, Kei; Seki, Masafumi; Takakura, Shunji; Tokimatsu, Issei; Ohmagari, Norio; Takahashi, Yoshiko; Matsumoto, Kazuaki; Igarashi, Masahiro; Kobayashi, Masahiro; Hamada, Yukihiro; Mochizuki, Takahiro; Kimura, Masao; Nishi, Yoshifumi; Tanigawara, Yusuke; Takesue, Yoshio.

In: Journal of Infection and Chemotherapy, Vol. 20, No. 1, 2014, p. 1-5.

Research output: Contribution to journalArticle

Okada, K, Kimura, T, Mikamo, H, Kasahara, K, Seki, M, Takakura, S, Tokimatsu, I, Ohmagari, N, Takahashi, Y, Matsumoto, K, Igarashi, M, Kobayashi, M, Hamada, Y, Mochizuki, T, Kimura, M, Nishi, Y, Tanigawara, Y & Takesue, Y 2014, 'Clinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring', Journal of Infection and Chemotherapy, vol. 20, no. 1, pp. 1-5. https://doi.org/10.1016/j.jiac.2013.08.008
Okada, Kenji ; Kimura, Toshimi ; Mikamo, Hiroshige ; Kasahara, Kei ; Seki, Masafumi ; Takakura, Shunji ; Tokimatsu, Issei ; Ohmagari, Norio ; Takahashi, Yoshiko ; Matsumoto, Kazuaki ; Igarashi, Masahiro ; Kobayashi, Masahiro ; Hamada, Yukihiro ; Mochizuki, Takahiro ; Kimura, Masao ; Nishi, Yoshifumi ; Tanigawara, Yusuke ; Takesue, Yoshio. / Clinical practice guidelines for therapeutic drug monitoring of arbekacin : A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. In: Journal of Infection and Chemotherapy. 2014 ; Vol. 20, No. 1. pp. 1-5.
@article{ea6bc92715f94534b78cc50f14e37fe4,
title = "Clinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring",
abstract = "Arbekacin (ABK) was approved and widely used in Japan for treatment of patients infected with MRSA, and TDM was introduced in clinical practice. The Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring decided to develop a clinical practice guidelines for TDM of ABK for the following reasons. First, although the daily dose of 150e200 mg was approved in Japan, recent PKPD studies revealed that higher serum concentration is required to achieve better clinical efficacy and several findings concerning the usefulness of higher dosage regimen have obtained recently. Second, although maximal concentrations that obtained immediately after the end of administration (Cmax) was generally adopted, the serum concentration at 1 h after initiation of administration [peak serum concentration (Cpeak)] proved to be more suitable as an efficacy indicator of aminoglycosides. Lastly, as ABK is approved only in Japan, no international practice guideline for TDM has not been available in ABK to date. This guideline evaluated the scientific data associated with serum ABK monitoring and provided recommendations based on the available evidence. Potential limitations of this guideline, however, include the findings that few prospective clinical trials of TDM of ABK are available in the treatment of MRSAinfections and that most of the published literature describes observational studies.",
keywords = "Arbekacin, Guideline, MRSA, Therapeutic drug monitoring",
author = "Kenji Okada and Toshimi Kimura and Hiroshige Mikamo and Kei Kasahara and Masafumi Seki and Shunji Takakura and Issei Tokimatsu and Norio Ohmagari and Yoshiko Takahashi and Kazuaki Matsumoto and Masahiro Igarashi and Masahiro Kobayashi and Yukihiro Hamada and Takahiro Mochizuki and Masao Kimura and Yoshifumi Nishi and Yusuke Tanigawara and Yoshio Takesue",
year = "2014",
doi = "10.1016/j.jiac.2013.08.008",
language = "English",
volume = "20",
pages = "1--5",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Clinical practice guidelines for therapeutic drug monitoring of arbekacin

T2 - A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

AU - Okada, Kenji

AU - Kimura, Toshimi

AU - Mikamo, Hiroshige

AU - Kasahara, Kei

AU - Seki, Masafumi

AU - Takakura, Shunji

AU - Tokimatsu, Issei

AU - Ohmagari, Norio

AU - Takahashi, Yoshiko

AU - Matsumoto, Kazuaki

AU - Igarashi, Masahiro

AU - Kobayashi, Masahiro

AU - Hamada, Yukihiro

AU - Mochizuki, Takahiro

AU - Kimura, Masao

AU - Nishi, Yoshifumi

AU - Tanigawara, Yusuke

AU - Takesue, Yoshio

PY - 2014

Y1 - 2014

N2 - Arbekacin (ABK) was approved and widely used in Japan for treatment of patients infected with MRSA, and TDM was introduced in clinical practice. The Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring decided to develop a clinical practice guidelines for TDM of ABK for the following reasons. First, although the daily dose of 150e200 mg was approved in Japan, recent PKPD studies revealed that higher serum concentration is required to achieve better clinical efficacy and several findings concerning the usefulness of higher dosage regimen have obtained recently. Second, although maximal concentrations that obtained immediately after the end of administration (Cmax) was generally adopted, the serum concentration at 1 h after initiation of administration [peak serum concentration (Cpeak)] proved to be more suitable as an efficacy indicator of aminoglycosides. Lastly, as ABK is approved only in Japan, no international practice guideline for TDM has not been available in ABK to date. This guideline evaluated the scientific data associated with serum ABK monitoring and provided recommendations based on the available evidence. Potential limitations of this guideline, however, include the findings that few prospective clinical trials of TDM of ABK are available in the treatment of MRSAinfections and that most of the published literature describes observational studies.

AB - Arbekacin (ABK) was approved and widely used in Japan for treatment of patients infected with MRSA, and TDM was introduced in clinical practice. The Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring decided to develop a clinical practice guidelines for TDM of ABK for the following reasons. First, although the daily dose of 150e200 mg was approved in Japan, recent PKPD studies revealed that higher serum concentration is required to achieve better clinical efficacy and several findings concerning the usefulness of higher dosage regimen have obtained recently. Second, although maximal concentrations that obtained immediately after the end of administration (Cmax) was generally adopted, the serum concentration at 1 h after initiation of administration [peak serum concentration (Cpeak)] proved to be more suitable as an efficacy indicator of aminoglycosides. Lastly, as ABK is approved only in Japan, no international practice guideline for TDM has not been available in ABK to date. This guideline evaluated the scientific data associated with serum ABK monitoring and provided recommendations based on the available evidence. Potential limitations of this guideline, however, include the findings that few prospective clinical trials of TDM of ABK are available in the treatment of MRSAinfections and that most of the published literature describes observational studies.

KW - Arbekacin

KW - Guideline

KW - MRSA

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=84903724636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903724636&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2013.08.008

DO - 10.1016/j.jiac.2013.08.008

M3 - Article

C2 - 24486168

AN - SCOPUS:84903724636

VL - 20

SP - 1

EP - 5

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 1

ER -